Company intelligence / Profile preview

Micromet

Munich, Bavaria, Germany

Ownership: Private
Development stage: Other

Overview

Micromet’s lead asset blinatumomab, a BiTE molecule targeting CD19, achieved promising responses in clinical trials for hematologic malignancies, including minimal residual disease-positive acute lymphoblastic leukemia[3][5]. Post-acquisition, blinatumomab was approved for clinical use by Amgen.

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyMonoclonal antibody
Industry: Biotech

Partnerships

Bayer HealthCare PharmaceuticalsBoehringer IngelheimMedImmuneMerck SeronoNycomedSanofi

Beyond the preview

Go deeper on Micromet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micromet.

Explore the full profile